CytomX Therapeutics : Annual Meeting Rules of Conduct
May 15, 2024 at 04:24 pm EDT
Share
GENERAL INFORMATION AND RULES AND PROCEDURES FOR
THE CONDUCT OF CYTOMX THERAPEUTICS, INC.'S VIRTUAL ANNUAL MEETING OF
STOCKHOLDERS
May 15, 2024
To ensure an efficient virtual Annual Meeting (the "Annual Meeting") of CytomX Therapeutics, Inc. (the "Company"), and to make the discussions as inclusive of all attendees as possible, we ask you to comply with the following rules which govern this Annual Meeting. Attendees who fail to comply with these rules may be asked to leave the Annual Meeting.
You need not vote at this Annual Meeting if you have already voted by proxy but if you previously voted and now wish to change your vote, or if you have not yet voted, you may vote online during the meeting before the polls close by following the instructions on the screen and using the 16-digit control number that was included in your Notice of Access of Internet Availability of Proxy Materials or included in the instructions that accompanied your proxy material.
The business of the Annual Meeting will follow the order set forth in the agenda. When an item on the agenda is being considered, questions and comments should be limited to that item. If you have a question about one of the items in the agenda to be voted on, such question may be submitted in the field provided in the web portal before or during the time such item is being considered.
There will be an opportunity for general questions after the formal meeting has been adjourned and you can submit general questions at any time by entering them in the field provided in the web portal.
Only stockholders (or holders of their proxies) eligible to vote at the Annual Meeting may submit questions at the Annual Meeting.
Questions and comments unrelated to the Annual Meeting agenda items should be held until the question and answer session following the Annual Meeting. Only stockholders (or holders of their proxies) eligible to vote at the Annual Meeting may submit questions during the question and answer session. Out of consideration for others, stockholders will be limited to three questions each. Questions should be related to matters of interest to all stockholders and should be appropriate for this Annual Meeting. Management and the Board of Directors will determine whether a question posed during the question and answer session is appropriate for discussion at the Annual Meeting.
The use of audio or video recording equipment is prohibited, except those employed by the Company to provide a record of the proceedings.
The views and comments of all stockholders are welcome. However, the purpose of the meeting will be observed, and the chairperson or secretary will not entertain questions that are:
irrelevant to the business of the Company or conduct of its operations;
related to pending or threatened litigation, if any;
derogatory references that are not in good taste;
substantially repetitious of statements made by other stockholders; or
discussions related to personal grievances.
Attachments
Original Link
Original Document
Permalink
Disclaimer
CytomX Therapeutics Inc. published this content on
15 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
15 May 2024 20:23:34 UTC.
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
CYTOMX THERAPEUTICS, INC. 
